HSBC Holdings’s Arcturus Therapeutics ARCT Stock Holding History

HSBC Holdings’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$396K	Sell	52,825 -13,306	-20%	-$97.1K	﹤0.01%	2326
2025 Q4	$402K	Buy	66,131 +42,148	+176%	+$455K	﹤0.01%	2404
2025 Q3	$440K	Sell	23,983 -8,385	-26%	-$135K	﹤0.01%	2169
2025 Q2	$425K	Buy	32,368 +9,208	+40%	+$109K	﹤0.01%	2234
2025 Q1	$248K	Sell	23,160 -2,208	-9%	-$35K	﹤0.01%	2497
2024 Q4	$424K	Buy	25,368 +2,673	+12%	+$50.3K	﹤0.01%	2280
2024 Q3	$525K	Buy	+22,695	New	+$486K	﹤0.01%	1982
2024 Q2	–	Sell	-7,656	Closed	-$258K	–	2929
2024 Q1	$258K	Buy	7,656 +1,286	+20%	+$45.6K	﹤0.01%	2537
2023 Q4	$202K	Buy	+6,370	New	+$151K	﹤0.01%	2469

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's ARCT Position: Q1 2026 in Review

HSBC Holdings reduced its Arcturus Therapeutics (ARCT) stake by 20% in Q1 2026, selling an estimated $97.1K and leaving 52,825 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

HSBC Holdings first reported a position in ARCT in Q4 2023 and has held it in 9 quarters since. The position peaked at $525K in Q3 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

HSBC Holdings held 52,825 shares of Arcturus Therapeutics worth $396K as of Q1 2026.
HSBC Holdings sold 13,306 Arcturus Therapeutics shares in Q1 2026, an estimated $97.1K.
Arcturus Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2326 holding.
HSBC Holdings first reported a position in Arcturus Therapeutics in Q4 2023 and has held it in 9 quarters since.
HSBC Holdings's Arcturus Therapeutics position peaked at $525K in Q3 2024.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.